ArticleMedComm2025

A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer.

Yalun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.